Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ANI PHARMACEUTICALS INC (ANIP)
|
|
| Segments |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues |
| Rare Disease | 41.7 | | | | | | | |
| Generics, Established Brands and Other | 274.7 | 216.1 | 208.5 | | | | | |
| United States | 312.4 | 211.9 | 202.9 | 199.7 | 196.9 | | | |
| Canada | 4.0 | 4.2 | 5.6 | 6.9 | 4.7 | | | |
| |
| EBITDA |
| Unallocated expenses | 21.7 | 7.5 | 28.6 | | | | | |
| |
| EBIT |
| Unallocated expenses | -35.3 | -39.8 | -16.0 | | | | | |
| |
| Mix |
| Rare Disease | 13.2% | | | | | | | |
| Generics, Established Brands and Other | 86.8% | 100.0% | 100.0% | | | | | |
| United States | 98.7% | 98.0% | 97.3% | 96.7% | 97.7% | | | |
| Canada | 1.3% | 2.0% | 2.7% | 3.3% | 2.3% | | | |
| |
| Growth |
| Generics, Established Brands and Other | 27.1% | 3.7% | | | | | | |
| United States | 47.4% | 4.4% | 1.6% | 1.4% | | | | |
| Canada | -6.7% | -24.2% | -18.7% | 46.8% | | | | |
|